Siderosis

01/01/2022 - "In those with cardiac siderosis (baseline T2* < 20 ms), there was an improvement in T2*-10.9 ± 5.9 to 13.5 ± 8.7 ms, P = 0.005-and fewer were classified as having clinically important cardiac iron loading (T2* < 20 ms, 24% vs. 16%, P < 0.001). "
10/01/2010 - "Patients with mild to moderate liver siderosis improved their cardiac T2* while more severely siderotic patients did not, regardless of initial cardiac iron burden. "
08/01/2013 - "We looked at the change in cardiac T2*, liver iron concentration (LIC) and left ventricular ejection fraction (LVEF) at years 3 and 5. In patients with severe cardiac siderosis, cardiac T2* (mean ± SD) improved from 6.9 ± 1.6 at baseline to 13.6 ± 10.0 by year 5, mean ΔT2* = 6.7 (P = 0.04). "
08/01/2010 - "Recent technologic advances in the documentation of organ-specific siderosis and the improved efficiency of iron chelating programs resulted in a spectacular improvement in the prevention of iron-induced end-organ failure and improved survival in thalassemic patients."
01/01/2021 - "Superficial siderosis can be more accurately diagnosed with imaging studies, and treatment using iron chelation has recently been studied but has not yet been established as an effective treatment. "

05/01/2022 - "Deferiprone administration significantly improved radiological and clinical outcomes in patients with postoperative superficial siderosis. "
07/09/2013 - "Further studies are required to assess the clinical efficacy of deferiprone in superficial siderosis. "
01/01/2012 - "Prospectively designed efficacy studies are necessary to determine the clinical efficacy of deferiprone in superficial siderosis."
01/01/2012 - "Pilot safety trial of deferiprone in 10 subjects with superficial siderosis."
05/01/2022 - "Fifteen postoperative patients with superficial siderosis were recruited, and seven patients were administered deferiprone (combination therapy group). "

09/01/1995 - "Electron microscopic studies of unstained sections showed early parenchymal cell siderosis, with accumulation of numerous ferritin particles and clusters in the cytosol, as well as ferritin and haemosiderin in lysosomes (siderosomes). "
01/01/2023 - "Gastric Glandular Siderosis but not Lamina Propria Siderosis is Associated With High Serum Ferritin Levels."
01/01/2023 - "However, when combining the R2* pancreas cut off ≤ 50 Hertz and a ferritin ≤ 1222 ng/ml, we could reach a negative predictive value (NPV) of 98% for cardiac siderosis. "
06/01/2019 - "Exploratory analyses showed serum ferritin thresholds for liver siderosis detected by MRI at approximately 300 ng/mL higher in MDS than in TM. "
01/01/2016 - "Serum ferritin ranged from 1200 to 8000 ng/ml, and mean T2* value was 27.10 ± 11.20 ms. Of patients, 68 (68%) had no cardiac siderosis, while 24 (24%) with mild to moderate, and 8 (8%) with sever cardiac siderosis. "

05/01/2007 - "By using cardiac T2 (*) MRI it was possible to examine the specific effect of a chelator on myocardial siderosis. "
05/01/2006 - "Differential effects on myocardial siderosis may exist between different chelators. "
06/01/1962 - "[The chelating agents in siderosis]."
08/04/1978 - "In spite of the treatment with the chelating agent secondary siderosis developed with typical endocrinological abnormalities and cardiac arrhythmias. "
01/01/2020 - "However, whilst chelators that strongly scavenge intracellular iron protect against oxidative neuronal damage in mammalian models and are proven to be effective in treating systemic siderosis, these compounds are not clinically suitable due to the high risk of developing iatrogenic iron depletion and ensuing anaemia. "

04/15/2010 - "pancreatic siderosis can be detected by T2* gradient-echo MRI since childhood in thalassemic patients, and is more evident in patients with abnormal glucose tolerance. "
04/15/2010 - "Significant reduction in signal intensity ratio (SIR) of the liver and the pancreas was shown in thalassemic patients compared to controls (P < 0.0001), Thalassemic patients with abnormal glucose tolerance; including diabetics and thalassemics with impaired glucose tolerance; displayed a higher degree of pancreatic and hepatic siderosis compared to thalassemics with normal glucose tolerance or controls (P < 0.001, P < 0.0001). "
06/01/2007 - "The study aims at describing the MR features of pancreas in beta-thalassemia major, investigating the relations between MR findings and glucose disturbances and between hepatic and pancreatic siderosis. "
05/01/2019 - "• Pancreatic iron might serve as an early predictor of cardiac siderosis and is the strongest overall predictor of glucose dysregulation."
01/01/2013 - "All patients showed significant reduction in the signal intensity of the liver and the pancreas on T2(∗)GRD compared to controls, thalassemic patients who had abnormal glucose tolerance; diabetic and impaired glucose tolerance patients displayed a higher degree of pancreatic and hepatic siderosis and more T2(∗) drop in their signal intensity than those with normal blood sugar level. "

06/18/2015 - "HYPERION, an open-label single-arm prospective phase 2 study, evaluated combination DFX-deferoxamine (DFO) in patients with severe transfusional myocardial siderosis (myocardial [m] T2* 5-<10 ms; left ventricular ejection fraction [LVEF] ≥56%) followed by optional switch to DFX monotherapy when achieving mT2* >10 ms. Mean dose was 30.5 mg/kg per day DFX and 36.3 mg/kg per day DFO on a 5-day regimen. "
01/01/1965 - "[LATEST CONTRIBUTION TO THE STUDY OF THE USE OF DESFERRIOXAMINE B AS A TEST FOR DETERMINATION OF STATES OF SIDEROSIS]."
02/25/2008 - "T2* cardiovascular magnetic resonance (CMR) was performed in 167 TM patients receiving standard subcutaneous deferoxamine monotherapy, and 22 had severe myocardial siderosis (T2* < 8 ms) with impaired left ventricular (LV) function. "
08/23/2002 - "However, complete regression of organ siderosis was achieved by deferoxamine administration. "
04/01/1986 - "For the treatment of transfusion siderosis she was given 18 high dose courses each comprising 35 g of desferrioxamine. "

10/01/2019 - "Although full-field electroretinogram (ffERG) is the gold standard test to detect physiological dysfunction in siderosis, it measures overall retinal function. "
12/04/1975 - "An experimental study on the retinal lesions in cases of siderosis bulbi (author's transl)]."
04/01/1969 - "[Studies on the primary lesion of experimental retinal siderosis. "
03/01/1969 - "[Studies on the primary lesion of the experimental retinal siderosis. "
02/01/1969 - "[Studies on the primary lesion of experimental retinal siderosis. "

05/01/2001 - "Magnetic resonance imaging studies revealed hemosiderin deposition, characteristic of superficial siderosis, and multiple cavernous malformations in all three cases. "
11/28/2023 - "In addition, ventral spinal CSF leaks are a possible etiology of superficial siderosis (SS), a rare condition characterized by hemosiderin deposits in the central nervous system (CNS). "
08/29/2023 - "However, the lack of hemosiderin deposition in the brain stem and cerebellar hemisphere was atypical of the classical type of superficial siderosis. "
06/01/2023 - "Superficial siderosis (SS) of the central nervous system constitutes linear hemosiderin deposits in the leptomeninges and the superficial layers of the cerebrum and the spinal cord. "
05/29/2023 - "Superficial siderosis is the deposition of hemosiderin in the superficial layers of the central nervous system. "

11/01/2014 - "Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study."
01/01/2017 - "In two patients with severe cardiac siderosis, a clinically relevant improvement in myocardial T2* was seen, following phlebotomy and deferasirox therapy (n = 1 each). "
02/01/2015 - "In a 1-year nonrandomized extension to the CORDELIA study, data collected from patients with myocardial siderosis provided additional information on deferasirox or deferoxamine (DFO) efficacy and safety. "
02/01/2011 - "Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major."
01/01/2011 - "Continuous treatment with deferasirox for two years with a target dose of 40 mg/kg/d continued to remove iron from the heart in patients with β-thalassemia major and mild, moderate and severe cardiac siderosis. "

09/13/2016 - "Cortical superficial siderosis: Prevalence and biomarker profile in a memory clinic population."
10/15/2008 - "Here we present the first report of a patient with superficial CNS siderosis in whom cerebrospinal fluid biomarkers of brain damage were assessed. "
01/01/2023 - "Cerebrospinal fluid biomarkers of superficial siderosis in patients with spontaneous intracranial hypotension."
01/01/2021 - "The following cerebral SVD biomarkers were detected on a 3-T brain MRI performed at baseline: white matter hyperintensities (WMHs), deep and lobar microbleeds, enlarged perivascular spaces in basal ganglia and centrum semiovale, previous small deep infarcts, and cortical superficial siderosis (cSS). "
01/01/2019 - "Typical cerebral MRI findings include lobar intracerebral hemorrhages and neuroimaging biomarkers of CAA (lobar cerebral microbleeds, cortical superficial siderosis, white matter hyperintensities, dilated perivascular spaces and microinfarcts). "

01/25/2012 - "In patients with severe cardiac siderosis, substantial improvement in RVEF was seen with open-label combination therapy (10.5% ± 5.6%, p < 0.01). "
09/25/2023 - "There was no relationship between oral anticoagulation therapy and the frequency of cortical superficial siderosis (p = 0.634). "
01/01/2023 - "Antithrombotic Therapy in Patients With Cerebral Microbleeds or Cortical Siderosis: Is This Contraindicated?"
01/01/2020 - "We report a case of biopsy proven symptomatic pulmonary siderosis in scissors/knife sharpening worker, who was unnecessarily treated with antitubercular therapy for 3 months."
01/01/2018 - "Linking cardiac siderosis measured by T2* to therapy improves outcomes. "

05/01/2023 - "All patients were on chelation therapy and only 3 TM patients had mild-to-severe cardiac siderosis. "
01/01/2023 - "Chelation therapy significantly reduced cardiac siderosis in thalassaemic patients. "
11/01/2020 - "Cardiac T2* MRI (T2*CMR), for accurate estimation of myocardial siderosis, was introduced as part of a QI collaborative to optimise chelation therapy in order to improve cardiac morbidity in transfusion dependent thalassaemia (TDT) patients. "
10/01/2018 - "We hypothesized that markers of endocrine dysfunction would correlate with T2* CMR and can be used to predict the severity of myocardial siderosis and guide chelation therapy. "
11/01/2016 - "Eight patients had siderosis and underwent chelation therapy. "

12/01/2020 - "This study aimed to establish outcomes following cochlear implantation (CI) in patients with superficial siderosis (SS). "
12/01/2014 - "The purpose of this study is to report an additional case of cochlear implantation in a patient with superficial siderosis and to contribute to the current literature available on outcomes of implantation in these individuals. "
09/01/2010 - "The purpose of this study is to present follow-up on a previously reported case of successful cochlear implantation in a patient with superficial siderosis. "
05/01/2021 - "A Case of Cochlear Implantation in a Patient with Superficial Siderosis."
12/01/2020 - "Outcomes of Cochlear Implantation in Patients with Superficial Siderosis: A Systematic Review and Narrative Synthesis."

05/28/2020 - "In conclusion, pigment lasers are an effective and safe method to treat cutaneous siderosis."
05/28/2020 - "The aims of this study were to assess the response of cutaneous siderosis to treatment with pigment lasers and to determine the optimal wavelength, number of treatment sessions and pulse duration. "
05/28/2020 - "Successful Treatment of Iatrogenic Cutaneous Siderosis with Pigment Lasers: A Retrospective Study in 15 Consecutive Patients."
07/01/2015 - "Q-switched lasers have been used effectively to treat lentigines and tattoos however, there is little data on the treatment of cutaneous siderosis with lasers. "

04/01/2016 - "The remarkable improvement in Abbreviated Profile of Hearing Aid Benefit scores shown in this study indicates that cochlear implantation leads to a better quality of life in superficial siderosis patients."
12/01/2012 - "The initial management of a patient with hearing loss secondary to superficial siderosis involves sound amplification using hearing aids. "